PDGFRB and inflammation: To evaluate the impact of impaired PDGFRβ signaling on allergic inflammation, we treated mice with the tyrosine kinase inhibitor CP-673451, which selectively inhibits PDGFRβ (27), in the context of HDM exposure for a period of 3 consecutive wk (Fig. 1A).